User contributions for Edzelco
Jump to navigation
Jump to search
1 February 2024
- 16:0816:08, 1 February 2024 diff hist 0 N File:Mitapivat 5mg tablet blister pack.png No edit summary current
- 16:0716:07, 1 February 2024 diff hist 0 N File:Mitapivat 20mg.png No edit summary current
- 16:0716:07, 1 February 2024 diff hist 0 N File:Mitapivat 20mg tablet blister pack.png No edit summary current
- 16:0716:07, 1 February 2024 diff hist 0 N File:Mitapivat 50mg.png No edit summary current
- 16:0716:07, 1 February 2024 diff hist 0 N File:Mitapivat 50mg tablet blister pack.png No edit summary current
- 16:0616:06, 1 February 2024 diff hist 0 N File:Mitapivat structure.png No edit summary current
- 16:0616:06, 1 February 2024 diff hist 0 N File:Mitapivat supply.png No edit summary current
- 15:4615:46, 1 February 2024 diff hist +21 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 15:4615:46, 1 February 2024 diff hist +26,967 N Sutimlimab-jome Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Sutimlimab-jome |aOrAn=a |drugClass=classical complement inhibitor |indicationType=treatment |indication=hemolysis in adults with cold agglutinin disease (CAD) |adverseReactions=in the CADENZA study (Part A) (incidence ≥18%) are rhinitis, headache, hypertension, acrocyanosis, and Raynaud's phenomenon. The most common adverse reactions in the CARDINAL study (incidence ≥..." current
- 15:4415:44, 1 February 2024 diff hist 0 N File:Sutimlimab-jome packaging.png No edit summary current
- 15:3215:32, 1 February 2024 diff hist +20 User:Edzelco No edit summary
- 15:3115:31, 1 February 2024 diff hist +24,023 N Faricimab-svoa Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Faricimab-svoa |aOrAn=a |drugClass=vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2) inhibitor |indicationType=treatment |indication=patients with neovascular (wet) age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO) |adverseReactions=cataract (15%) and [[conjunctival hemorrhage]..." current
- 15:0515:05, 1 February 2024 diff hist +32 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 15:0515:05, 1 February 2024 diff hist −1 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 15:0415:04, 1 February 2024 diff hist +25 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 15:0415:04, 1 February 2024 diff hist +17 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 15:0315:03, 1 February 2024 diff hist +16 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 15:0315:03, 1 February 2024 diff hist +31 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 15:0215:02, 1 February 2024 diff hist +31 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 15:0215:02, 1 February 2024 diff hist +18 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 15:0115:01, 1 February 2024 diff hist +18 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 15:0015:00, 1 February 2024 diff hist +17 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 15:0015:00, 1 February 2024 diff hist +22 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 14:5914:59, 1 February 2024 diff hist +18,438 N Tebentafusp-tebn Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Tebentafusp-tebn |aOrAn=a |drugClass=bispecific gp100 peptide-HLA-directed CD3 T cell engager |indicationType=treatment |indication=HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma |hasBlackBoxWarning=Yes |adverseReactions=cytokine release syndrome, rash, pyrexia, pruritus, fatigue, nausea, chills, abdominal pain, edema, hypotension, dry skin, headache and vomiting. The most..." current
- 01:4901:49, 1 February 2024 diff hist +604 Abrocitinib No edit summary current
- 01:4601:46, 1 February 2024 diff hist +13,636 Abrocitinib No edit summary
- 01:4601:46, 1 February 2024 diff hist 0 N File:Abrocitinib 200mg.png No edit summary current
- 01:4601:46, 1 February 2024 diff hist 0 N File:Abrocitinib 100mg.png No edit summary current
- 01:4301:43, 1 February 2024 diff hist 0 N File:Abrocitinib 50mg.png No edit summary current
- 01:3901:39, 1 February 2024 diff hist 0 N File:Abrocitinib supply.png No edit summary current
- 01:3201:32, 1 February 2024 diff hist 0 N File:Abrocitinib.png No edit summary current
- 01:3101:31, 1 February 2024 diff hist +22,842 N Abrocitinib Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |indicationType=treatment |indication=adults and pediatric patients 12 years of age and older with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable. |blackBoxWarningTitle=WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE), and THROMBOS..."
- 01:0601:06, 1 February 2024 diff hist −279 Daridorexant No edit summary current
31 January 2024
- 21:1721:17, 31 January 2024 diff hist +31,199 N Daridorexant Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=daridorexant |aOrAn=an |drugClass=orexin receptor antagonist |indicationType=treatment |indication=adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance |adverseReactions=Common adverse reactions (reported in ≥ 5% of patients treated with QUVIVIQ and at an incidence ≥ than placebo) include headache and somnolence or fatigue..."
- 21:1521:15, 31 January 2024 diff hist 0 N File:Clinical Studies 3.png No edit summary current
- 21:1521:15, 31 January 2024 diff hist 0 N File:Clinical Studies 2.png No edit summary current
- 21:1521:15, 31 January 2024 diff hist 0 N File:Clinical Studies 1.png No edit summary current
- 21:0721:07, 31 January 2024 diff hist 0 N File:Effects of hepatic impairment and renal impairment on daridorexant PK.png No edit summary current
- 21:0721:07, 31 January 2024 diff hist 0 N File:Effect of daridorexant on the PK of other compounds.png No edit summary current
- 21:0621:06, 31 January 2024 diff hist 0 N File:Effect of co-administered compounds on the PK of daridorexant.png No edit summary current
- 21:0121:01, 31 January 2024 diff hist 0 N File:Packaging 3.png No edit summary current
- 21:0121:01, 31 January 2024 diff hist 0 N File:Packaging 2.png No edit summary current
- 21:0021:00, 31 January 2024 diff hist 0 N File:Packaging 1.png No edit summary current
- 20:4920:49, 31 January 2024 diff hist 0 N File:Daridorexant.png No edit summary current
25 January 2024
- 00:2500:25, 25 January 2024 diff hist +5,566 N Orbifloxacin Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Orbifloxacin |aOrAn=a |drugClass=fluoroquinolone carboxylic acid derivatives |indicationType=treatment |indication=urinary tract infections (cystitis) in dogs caused by susceptible strains of <i>Staphylococcus pseudintermedius, Proteus mirabilis, Escherichia coli</i> and <i>Enterococcus faecalis</i>. |adverseReactions=In a field study, when the tablet formulation of orbifloxacin..." current
- 00:1600:16, 25 January 2024 diff hist 0 N File:Orbifloxacin packaging.png No edit summary current
- 00:1500:15, 25 January 2024 diff hist 0 N File:Orbifloxacin suspension 2.png No edit summary current
- 00:1500:15, 25 January 2024 diff hist 0 N File:Orbifloxacin suspension.png No edit summary current
- 00:1500:15, 25 January 2024 diff hist 0 N File:Orbifloxacin structure.png No edit summary current
23 January 2024
- 14:2814:28, 23 January 2024 diff hist +30,972 N Ado-Trastuzumab Emtansine Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Ado-trastuzumab emtansine |aOrAn=a |drugClass=HER2-targeted antibody and microtubule inhibitor conjugate |indicationType=treatment |indication=1.) patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: a.) Received prior therapy for metastatic disease, or b.) Developed disease recurrence during or wi..." current